U.S. Markets close in 32 mins.

Taro Pharmaceutical Industries Ltd. (TARO)

New York Stock Exchange Consolidated Issue - Nasdaq Real Time Price. Currency in USD
Add to watchlist
104.0500+2.5000 (+2.4618%)
As of 3:26PM EDT. Market open.
People also watch

Taro Pharmaceutical Industries Ltd.

14 Hakitor Street
Haifa 2624761
972 4 847 5700

IndustryDrug Manufacturers - Other
Full Time Employees1,413

Key Executives

Mr. Michael PerfettoGroup VP604.09kN/A56
Mr. Ara AprahamianExec. Officer602kN/AN/A
Mr. Uday V. BaldotaCEO & DirectorN/AN/A47
Mr. Abhay GandhiVice Chairman & Interim CEON/AN/A52
Mr. Mariano BalaguerVP, CFO & Chief Accounting OfficerN/AN/A44
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Sun Pharmaceutical Industries Ltd.

Corporate Governance

Taro Pharmaceutical Industries Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.